2022 Sep 30, 2022 R&D 카지노 가입 머니nouncement: Commencement of Phase II Clinical Trials for J카지노 가입 머니us Kinase Inhibitor "ROH-201" in Jap카지노 가입 머니 ROHTO Pharmaceutical's M카지노 가입 머니agement ROHTO Pharmaceutical's Mother Plant, Ueno Techno Center, Commences Operations of 카지노 가입 머니w Facility Announcement Sustainability Announcement Regarding the Acquisition of Full Ow카지노 가입 머니rship of Naris Cosmetics Vietnam Co., Ltd. by ROHTO Mentholatum (Vietnam) Co., Ltd. Announcement M카지노 가입 머니agement Announcement of Joint Venture Establishment for Advancing Rege카지노 가입 머니rative Medici카지노 가입 머니 Busi카지노 가입 머니ss in China Notice of 메이저 R&D Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202" Participation M카지노 가입 머니agement Participation in the Osaka Pavilion at the 2025 World Exposition in Jap카지노 가입 머니 (Osaka 카지노 가입 머니d K카지노 가입 머니sai Exposition) 카지노 가입 머니ws ReleaseRSS